A Macrocyclic Agouti-Related Protein/[Nle<sup>4</sup>,DPhe<sup>7</sup>]α-Melanocyte Stimulating Hormone Chimeric Scaffold Produces Subnanomolar Melanocortin Receptor Ligands.
Ericson. Mark D MD; Freeman. Katie T KT; Schnell. Sathya M SM; Haskell-Luevano. Carrie C
Key Findings
- A library of 14 chimeric AGRP/NDP‑MSH peptides was created and tested on mouse melanocortin receptors.
- Two peptides showed nanomolar agonist potency at the mouse MC4R, a receptor involved in appetite regulation.
- These compounds are proposed as probes for studying obesity mechanisms, not as finished therapies.
Practical Outcomes
- The work shows it’s possible to design tiny peptides that activate MC4R, which could eventually lead to new weight‑loss agents, but there’s no actionable protocol for biohackers right now. Enthusiasts should view this as a proof‑of‑concept rather than a ready‑to‑use supplement.
Summary
Scientists made a set of hybrid peptides combining parts of natural hormones that affect appetite and metabolism, and found two that strongly activate a mouse receptor linked to weight control. However, these are early‑stage research tools, not ready for human use or dosing guidance.
Abstract
The melanocortin system consists of five receptor subtypes, endogenous agonists, and naturally occurring antagonists. These receptors and ligands have been implicated in numerous biological pathways including processes linked to obesity and food intake. Herein, a truncation structure-activity relationship study of chimeric agouti-related protein (AGRP)/[Nle4,DPhe7]α-melanocyte stimulating hormone (NDP-MSH) ligands is reported. The tetrapeptide His-DPhe-Arg-Trp or tripeptide DPhe-Arg-Trp replaced the Arg-Phe-Phe sequence in the AGRP active loop derivative c[Pro-Arg-Phe-Phe-Xxx-Ala-Phe-DPro], where Xxx was the native Asn of AGRP or a diaminopropionic (Dap) acid residue previously shown to increase antagonist potency at the mMC4R. The Phe, Ala, and Dap/Asn residues were successively removed to generate a 14-member library that was assayed for agonist activity at the mouse MC1R, MC3R, MC4R, and MC5R. Two compounds possessed nanomolar agonist potency at the mMC4R, c[Pro-His-DPhe-Arg-Trp-Asn-Ala-Phe-DPro] and c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro], and may be further developed to generate novel melanocortin probes and ligands for understanding and treating obesity.
Study Information
pubmed
2017
2017-01-17T00:00:00.000Z
10.1021/acs.jmedchem.6b01707
12
67